Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health - Report - MDSpire

Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health

  • By

  • Chi-Hsien Lee

  • Thi Phuong Nam Bui

  • Camille Petitfils

  • Ching Jian

  • Giselle C Wong

  • Anthony Puel

  • Tiphaine Le Roy

  • Samuel Bellais

  • Bouthaina Ben Abdallah

  • Mélanie Nehlich

  • Thomas Leicht

  • Manyi Jia

  • Lesley Hoyles

  • Massimo Federici

  • Jose Manuel Fernández-Real

  • Remy Burcelin

  • Marc-Emmanuel Dumas

  • Nathalie M Delzenne

  • Thomas Clavel

  • Sjef Boeren

  • Antonio Dario Troise

  • Andrea Scaloni

  • Giulio G Muccioli

  • Willem M De Vos

  • Matthias Van Hul

  • Patrice D Cani

  • July 1, 2026

  • 0 min

Share

Clinical Report: Unique Fermentation Pathway in Dysosmobacter welbionis

Overview

This study identifies Dysosmobacter welbionis as a gut bacterium capable of converting myo-inositol to butyrate, a short-chain fatty acid linked to metabolic and liver health. The findings suggest a potential protective role of D. welbionis in metabolic-associated fatty liver disease (MASLD) and highlight its relevance for future probiotic applications.

Background

Butyrate is essential for metabolic and liver health, produced by gut bacteria through fermentation processes. Dysosmobacter welbionis has been linked to improved metabolic outcomes, yet its specific metabolic pathways remained unexplored until now. Understanding these pathways could inform new therapeutic strategies for metabolic diseases.

Data Highlights

No numerical data or trial data provided in the article.

Key Findings

  • Dysosmobacter welbionis is prevalent in diverse human populations and shows heritability in monozygotic twins.
  • Its abundance is significantly reduced in patients with metabolic-associated fatty liver disease (MASLD).
  • A unique fermentation pathway converting myo-inositol to butyrate was identified in D. welbionis.
  • Advanced techniques were employed to isolate and analyze 23 human-derived strains of D. welbionis.
  • The study suggests D. welbionis could be a candidate for next-generation probiotics targeting metabolic diseases.

Clinical Implications

The findings indicate that enhancing the abundance of D. welbionis may offer a novel approach to managing metabolic diseases such as MASLD and type 2 diabetes. Clinicians should consider the potential of inositol supplementation and strain-specific probiotics in therapeutic strategies.

Conclusion

The discovery of the myo-inositol to butyrate pathway in Dysosmobacter welbionis underscores its ecological and therapeutic significance, paving the way for future research into its probiotic potential.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. The Journal of Infectious Diseases — The Role of Nutrition in Clostridioides difficile Infections: A Comprehensive Review
  3. Frontiers in Immunology — Reframing precision nutrition in irritable bowel syndrome: a mechanism-informed conceptual framework for responder prediction and clinical translation
  4. Journal of Gastroenterology — Bifidobacterium bifidum CIP-01 Reduces Liver Disease Linked to Metabolic Dysfunction Induced by High-Alcohol-Producing Klebsiella pneumoniae
  5. Frontiers in Immunology — Gut microbial bile salt hydrolase as a metabolic gatekeeper in digestive homeostasis and disease
  6. Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease | AASLD
  7. Fecal microbiota-based therapies for select gastrointestinal diseases - American Gastroenterological Association
  8. Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health - PubMed

Original Source(s)

Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health

  • by Chi-Hsien Lee, Thi Phuong Nam Bui, Camille Petitfils, Ching Jian, Giselle C Wong, Anthony Puel, Tiphaine Le Roy, Samuel Bellais, Bouthaina Ben Abdallah, Mélanie Nehlich, Thomas Leicht, Manyi Jia, Lesley Hoyles, Massimo Federici, Jose Manuel Fernández-Real, Remy Burcelin, Marc-Emmanuel Dumas, Nathalie M Delzenne, Thomas Clavel, Sjef Boeren, Antonio Dario Troise, Andrea Scaloni, Giulio G Muccioli, Willem M De Vos, Matthias Van Hul, Patrice D Cani

  • July 1, 2026

Related Content

The Heresy of Hypoabsorptive Bariatric Surgery: A Critical Reappraisal of Long-Term Outcomes and Clinical Trade-Offs

Frontline Pharma: Sarah O’Keeffe

Ahead of HPLC 2026, Eli Lilly’s Sarah O’Keeffe reflects on leadership, collaboration, and the analytical advances helping bring increasingly complex medicines to patients

Triphenyl phosphate promotes lipid accumulation in human mesenchymal stem cells through metabolic stress pathways